Project Grant R01CA287778
Award Date
6/10/24
Completion Date
5/31/29
Dollars Obligated
$661K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $693,156 Project Grant (R21EB035247) to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop artificial intelligence (AI) algorithms to predict prognosis and aid in treatment selection for cutaneous squamous cell carcinoma (CSCC), a highly prevalent form of skin cancer. The project, funded under the NIBIB's "Discovery and Applied Research for Technological Innovations to Improve Human Health"...
This $962,560 Project Grant (R01CA285369) awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to modify and clinically validate the IRIS device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMICs). The key products and services to be delivered include: 1) Modifying the existing IRIS prototype to include an endocervical...
The National Cancer Institute (NCI) awarded a $968,999 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of North Carolina at Chapel Hill (UNC-CH) to optimize imaging-based surveillance strategies for lung cancer survivors. The 5-year project aims to develop and validate risk prediction models that incorporate novel imaging biomarkers from routine CT scans to personalize post-treatment surveillance and detect recurrent or new lung cancer at...
This $1,625,000 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development and validation of a radiomics-based, multi-modal predictive model for assessing response to PD-1/PD-L1 immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study; 2) Evaluate the performance...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida, provides $299,995.00 to develop innovative, non-invasive biomarkers from standard-of-care CT imaging that can predict survival outcomes for patients with high-grade serous ovarian carcinoma (HGSOC). The researchers will build upon an existing multi-institutional patient cohort, utilize...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $388,673 to The University of Kentucky Research Foundation to develop novel statistical methods to identify and evaluate predictive biomarkers for cancer treatment response using paired progression-free survival (PFS) data from non-randomized Phase II clinical trials. The key objectives are to: a) develop semiparametric statistical models to identify and combine...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $244,228 to The University of Texas MD Anderson Cancer Center to develop a functional proteomics approach for accurately mapping lung cancer patient tumors to preclinical models. The key objectives are to: 1) expand proteomics profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein array (RPPA) technology, which...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $704,563 to the Beckman Research Institute of the City of Hope to develop a quantitative MRI (qMRI) toolset and automated prostate cancer tumor segmentation method. The key products and services to be delivered through this 5-year project include: Building a qMRI toolset using magnetic resonance fingerprinting, arterial spin labeling, and diffusion-weighted MRI to generate...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $679,188 to The Regents of the University of California, San Francisco to develop liquid biopsy tools for evaluating known biomarkers and discovering new predictive biomarkers and drug targets associated with malignant effusions (ME) in metastatic breast cancer. The key objectives are to: 1) Validate an AI-assisted, morphology-based platform to isolate ME-derived...